Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of the Axiom™ Genome-Wide ASI Array, the first commercial product to provide maximum power for genome-wide association studies (GWAS) in East Asian populations. This array is the second catalog release for the Axiom™ Genotyping Solution, which includes a suite of population-optimized arrays for genomic studies that will be delivered in the next year.

The Axiom Genome-Wide ASI Array enables researchers to characterize the genetic basis of disease in Asian populations and also offers high genomic coverage for Caucasian populations, making it a powerful, high-throughput tool for ancestry, population, and personal genomic studies.

“There is evidence that differences in disease frequencies and intensity within different populations may have a genetic basis,” said Dr. Edison Liu, Executive Director of the Genome Institute of Singapore (GIS), which is using the Axiom Genome-Wide ASI Array in ongoing studies to explore the genetic basis of disease in East Asian populations.

“The increase in knowledge of population-specific human genetic variation is paying off with the creation of GWAS arrays optimized for specific populations,” said Dr. Liu, adding that he is pleased with this advanced approach to genome-wide array design.

“This offers researchers increased power to detect population-specific allele associations. With the dramatically increased intensity of research in population genetics in Asia, the Axiom Genome-Wide ASI Array will offer tailored precision for the identification of disease alleles.”

The Genome-Wide ASI Array optimizes genomic coverage with known disease association markers, chromosomes X and Y, mitochondrial genomes, and ADME genes. Content was drawn from the 1000 Genomes Project as well as Han Chinese and Tokyo Japanese data made available through the International HapMap Project.

Dr. Jianjun Liu, Group Leader and Associate Director of the Human Genetics group at GIS, is pleased with the performance of the Axiom Genome-Wide ASI Array. “We have run more than 1,000 samples with average call rates above 99.7 percent and HapMap concordance in excess of 99.8 percent,” said Dr. Jiu.

The complete Axiom Genotyping Solution consists of Axiom ASI Array Plates, complete Axiom Reagent Kits, an automated target preparation station developed jointly by Affymetrix and Beckman Coulter, and the GeneTitan® Instrument. The GeneTitan Instrument integrates a hybridization oven, fluidics processing, CCD imaging device, and analysis software for maximum data reproducibility, user productivity, and scalability. Scientists can run more than 760 samples per week with minimal user intervention, a significant advantage over competing products.

“The ASI Array offers a complete solution to researchers looking for novel genetic variations associated with complex disease in East Asian populations,” said Kevin King, president and CEO. “This solution is ideally suited to customers interested in exploring the genetic complexities underlying disease in Asian populations. We look forward to further expanding the Axiom family of genotyping products in the future.”

For more information about Axiom Genotyping Solution, please visit www.affymetrix.com/axiom

Beckman Coulter ® and Biomek ® are registered trademarks of Beckman Coulter, Inc. Beckman Coulter Biomek Systems are for Laboratory Use Only; not for use in diagnostic procedures.

About Affymetrix

Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.

About the Genome Institute of Singapore

The Genome Institute of Singapore (GIS) is a member of the Agency for Science, Technology and Research (A*STAR). It is a national initiative with a global vision that seeks to use genomic sciences to improve public health and public prosperity. Established in 2001 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards the goal of individualized medicine. The key research areas at the GIS include Systems Biology, Stem Cell & Developmental Biology, Cancer Biology & Pharmacology, Human Genetics, Infectious Diseases, Genomic Technologies, and Computational & Mathematical Biology. The genomics infrastructure at the GIS is utilized to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact. For more information, visit the GIS website: www.gis.a-star.edu.sg.

Forward-looking statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports for subsequent quarterly periods.

NOTE: Affymetrix, the Affymetrix logo, Axiom, and GeneTitan are trademarks or registered trademarks of Affymetrix Inc.

Copyright Business Wire 2010